PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
The current price of PEPG is $1.77 USD — it has increased by +4.73% in the past 24 hours. Watch PepGen stock price performance more closely on the chart.
What is PepGen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PepGen stocks are traded under the ticker PEPG.
Is PepGen stock price growing?▼
PEPG stock has risen by +6.59% compared to the previous week, the month change is a -66.57% fall, over the last year PepGen has showed a +61.82% increase.
What is PepGen market cap?▼
Today PepGen has the market capitalization of 121.68M
When is the next PepGen earnings date?▼
PepGen is going to release the next earnings report on May 07, 2026.
What were PepGen earnings last quarter?▼
PEPG earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.35 USD resulting in a +23.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PepGen revenue for the last year?▼
PepGen revenue for the last year amounts to 0 USD.
What is PepGen net income for the last year?▼
PEPG net income for the last year is -179.96M USD.
How many employees does PepGen have?▼
As of April 14, 2026, the company has 79 employees.